Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Best-corrected visual acuity of at least 20/80 in both eyes~* Age above 17 years~* Use of active contraceptive methods for women in their reproductive phase of life~* Complete demographic and baseline information (Eligibility Visit)~* IOP ≥ 18 mm Hg and ≤ 36 mm Hg~* Significant visual field loss in the previous year~* Uncontrolled systemic disease~* Active ocular disease or intraocular surgery within past three months~* Use of other medications with possible substantial effect on IOP~* Allergy/contraindication to any of the study components~* Severe glaucoma according to Hodapp's criteria~* Incapacity or unwillingness to participate in the study~Exclusion Criteria:~-Any ocular illness other than mild-moderate lens loss of transparency and glaucoma/ocular hypertension

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ganfort's Group (Type: None): Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)
- Krytantek's Group (Type: None): Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)

Based on this trial design, predict the completion outcome and termination type (if applicable).